CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity.

CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity. Oncol Rep. 2019 Feb 28;: Authors: Li Y, Zhao C, Liu J, Lu Z, Lu M, Gu J, Liu R Abstract Dendritic cells (DCs), as professional antigen‑presenting cells are essential for the initial activation of adaptive antitumor immunity. CD1d is considered to present phospholipid and glycosphingolipid antigens to NKT cells. However, it is currently unknown whether CD1d expression on DCs is capable of enhancing antitumor immunity, particularly T‑cell related immunity. We observed that CD1d was predominantly expressed on DCs in 3LL tumor‑bearing mice, whilst a deficiency of CD1d promoted tumor growth. Notably, CD1d expression on DCs was not only required for presenting antigen to NKT cells, but also markedly promoted CD4+T and CD8+T cell activation, particularly cytotoxic T cells. All the T cells (NKT, CD4+T and CD8+T cells) upregulated CD69, CD107a and IFN‑γ after the adoptive transfer of CD1d‑positive DCs (CD1d+DCs) and tumor growth was suppressed. With regard to the mechanism, we revealed that CD1d+DCs were concomitant with a higher expression of costimulatory molecules (CD40, CD80 and CD86) and MHCI/II, which are essential for DCs to present antigens to T cells. Consistently, CD1d+DCs displayed stronger activation‑associated‑ERK1/2 and NF‑κB signals; whereas JAK2‑STAT3/6 signaling was required for maintaining a high leve...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Publication date: 15 September 2019Source: Life Sciences, Volume 233Author(s): Humera Memon, Bhoomika M. PatelAbstractLung cancer is the leading cause of cancer-related mortality worldwide. Treatment with immunotherapy has made a significant impact on the outcomes for those patients suffering from lung cancer and its usage is currently an established treatment modality. Immune checkpoint inhibition that has blocking antibodies which target cytotoxic T-lymphocyte antigen-4 (CTLA-4) along with the programmed cell death protein 1 (PD-1) pathway [programmed death - 1/programmed death-ligand 1 (PD-L1)] have shown promising resu...
Source: Life Sciences - Category: Biology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at Asbestos.com. “Now, we still ha...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A new meta-analysis compared survival in patients with advanced  non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Squamous cell carcinoma, characterized by large keratinizing and atypical polygonal cells in the respiratory bronchial epithelium [1], affects 30% of patients with lung cancer [2]. Historically, patients with squamous NSCLC were treated with first-line platinum-based chemotherapy [3]. Unlike non-squamous NSCLC, there have been no validated, targetable oncogenic drivers to date. The development and recent approval of targeted immunotherapies, either alone or in combination with platinum-doublet chemotherapy based on improved overall survival, offer a new treatment approach for patients with advanced squamous NSCLC.[4,5] How...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion.NLR and PLR may predict the appearance of irAEs in non‐oncogene‐addicted aNSCLC, although this conclusion warrants prospective validation.Implications for Practice.This study was designed to investigate the role of blood biomarkers in predicting the occurrence of immune‐related adverse events (irAEs) in patients with advanced non‐small cell lung cancer receiving immunotherapy. The results of the study suggest a potential predictive role of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as markers for irAE development in this category of patients. These data provide rationale for ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
CONCLUSIONS: Pemetrexed augments systemic intra-tumor immune responses through tumor intrinsic mechanisms including immunogenic cell death, T cell-intrinsic mechanisms enhancing mitochondrial biogenesis leading to increased T cell infiltration/activation along with modulation of innate immune pathways, significantly enhanced in combination with PD-1 pathway blockade. PMID: 31409612 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Advancing treatments for complex and deadly diseases needs gene signatures to identify patients at risk under various genetic and clinical conditions. Our new prognosis gene signature for lung adenocarcinoma meets that need with risk ‐stratification ability on mutation status ofEGFR andTP53, levels of immune checkpointPD ‐L1 expression, and with and without adjuvant chemotherapy. This is a helpful step toward selecting an effective, personalized treatment plan for lung adenocarcinoma patients. AbstractThe overall survival rates for lung cancer remain unsatisfactorily low, even for patients with biomarkers for which tar...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionThe new HSV-1 based platform described provides a potent and versatile approach to developing new oncolytic immunotherapies for clinical use. Each of the modifications employed was demonstrated to aid in optimizing the potential of the virus to both directly kill tumors and to lead to systemic therapeutic benefit. For clinical use, these viruses are expected to be most effective in combination with other anti-cancer agents, in particular PD1/L1-targeted immune checkpoint blockade. The first virus from this program (expressing GALV-GP-R− and hGM-CSF) has entered clinical development alone and in combination ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Purpose of review The aim of this review is to provide an overview of the current development of immuno-oncology in the (neo)adjuvant setting. Recent findings Several checkpoint inhibitors (CPis) have been approved for the treatment of advanced solid cancers, mostly for unresectable metastatic setting. Thus, the next logical step is to explore the potential of CPi in earlier stages of the disease. Summary There are currently many ongoing trials investigating immunotherapy agents in the early setting in various tumor types, involving various CPis and other innovative immunotherapies, as well as combinations with eit...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer